Jump Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jump Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,692	Closed	-$13.6K	–	2289
2025 Q2	$13.6K	Buy	+11,692	New	+$15.4K	﹤0.01%	1731
2024 Q4	–	Sell	-33,557	Closed	-$123K	–	2074
2024 Q3	$123K	Buy	+33,557	New	+$122K	﹤0.01%	1515
2024 Q2	–	Sell	-118,648	Closed	-$1.87M	–	2347
2024 Q1	$1.87M	Buy	+118,648	New	+$1.63M	0.05%	484
2023 Q3	–	Sell	-31,570	Closed	-$891K	–	2321
2023 Q2	$891K	Sell	31,570 -14,125	-31%	-$339K	0.03%	739
2023 Q1	$786K	Buy	+45,695	New	+$925K	0.03%	705
2021 Q1	–	Sell	-8,600	Closed	-$447K	–	1348
2020 Q4	$447K	Buy	+8,600	New	+$388K	0.08%	417

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jump Financial's ZNTL Position: Q3 2025 in Review

Jump Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 11,692 shares — an estimated $13.6K sold.

Jump Financial first reported a position in ZNTL in Q4 2020 and held it in 6 quarters. The position peaked at $1.87M in Q1 2024. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Jump Financial reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jump Financial sold 11,692 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $13.6K.
Jump Financial first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Jump Financial's Zentalis Pharmaceuticals position peaked at $1.87M in Q1 2024.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.